ReP USP - Resultado da busca

Artigo de periodico
Distinct impact of DMARD combination and monotherapy in immunogenicity of an inactivated SARS-CoV-2 vaccine in rheumatoid arthritis (2022)
Medeiros-Ribeiro, Ana Cristina; Bonfiglioli, Karina Rossi; Domiciano, Diogo Souza; Shimabuco, Andrea Yukie; Silva, Henrique Carrico da; Saad, Carla G. S.; Yuki, Emily Figueiredo Neves; Pasoto, Sandra Gofinet; Araujo, Carlo Scognamiglio Renner; Nakai, Tatiane Lie; Silva, Clovis Artur Almeida da ; Kupa, Leonard de Vinci Kanda ; Kallas, Esper Georges ; Bonfa, Eloisa Silva Dutra de Oliveira
Source: Annals of the rheumatic diseases. Unidade: FM
Subjects: FÁRMACOS DO SANGUE E SISTEMA HEMATOPOÉTICO, ESTUDOS PROSPECTIVOS, SISTEMA IMUNE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MEDEIROS-RIBEIRO, Ana Cristina et al. Distinct impact of DMARD combination and monotherapy in immunogenicity of an inactivated SARS-CoV-2 vaccine in rheumatoid arthritis. Annals of the rheumatic diseases, v. 81, n. 5, p. 710-719, 2022Tradução . . Disponível em: https://doi.org/10.1136/annrheumdis-2021-221735. Acesso em: 10 nov. 2024.
APA
Medeiros-Ribeiro, A. C., Bonfiglioli, K. R., Domiciano, D. S., Shimabuco, A. Y., Silva, H. C. da, Saad, C. G. S., et al. (2022). Distinct impact of DMARD combination and monotherapy in immunogenicity of an inactivated SARS-CoV-2 vaccine in rheumatoid arthritis. Annals of the rheumatic diseases, 81( 5), 710-719. doi:10.1136/annrheumdis-2021-221735
NLM
Medeiros-Ribeiro AC, Bonfiglioli KR, Domiciano DS, Shimabuco AY, Silva HC da, Saad CGS, Yuki EFN, Pasoto SG, Araujo CSR, Nakai TL, Silva CAA da, Kupa L de VK, Kallas EG, Bonfa ESD de O. Distinct impact of DMARD combination and monotherapy in immunogenicity of an inactivated SARS-CoV-2 vaccine in rheumatoid arthritis [Internet]. Annals of the rheumatic diseases. 2022 ; 81( 5): 710-719.[citado 2024 nov. 10 ] Available from: https://doi.org/10.1136/annrheumdis-2021-221735
Vancouver
Medeiros-Ribeiro AC, Bonfiglioli KR, Domiciano DS, Shimabuco AY, Silva HC da, Saad CGS, Yuki EFN, Pasoto SG, Araujo CSR, Nakai TL, Silva CAA da, Kupa L de VK, Kallas EG, Bonfa ESD de O. Distinct impact of DMARD combination and monotherapy in immunogenicity of an inactivated SARS-CoV-2 vaccine in rheumatoid arthritis [Internet]. Annals of the rheumatic diseases. 2022 ; 81( 5): 710-719.[citado 2024 nov. 10 ] Available from: https://doi.org/10.1136/annrheumdis-2021-221735
Artigo de periodico
Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome (2022)
Signorelli, Flavio; Balbi, Gustavo Guimaraes Moreira; Aikawa, Nadia E; Silva, Clovis Artur Almeida da ; Kupa, Leonard de Vinci Kanda ; Medeiros-Ribeiro, Ana C; Yuki, Emily F. N; Pasoto, Sandra G; Saad, Carla G. S; Borba Neto, Eduardo Ferreira ; Bonfa, Eloisa Silva Dutra de Oliveira
Source: Lupus. Unidade: FM
Subjects: COVID-19, ANTICORPOS ANTIFOSFOLIPÍDEOS, IMUNOGENÉTICA, FATORES DE RISCO, COAGULAÇÃO SANGUÍNEA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SIGNORELLI, Flavio et al. Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome. Lupus, v. 31, n. 8, p. 974-984, 2022Tradução . . Disponível em: https://doi.org/10.1177/09612033221102073. Acesso em: 10 nov. 2024.
APA
Signorelli, F., Balbi, G. G. M., Aikawa, N. E., Silva, C. A. A. da, Kupa, L. de V. K., Medeiros-Ribeiro, A. C., et al. (2022). Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome. Lupus, 31( 8), 974-984. doi:10.1177/09612033221102073
NLM
Signorelli F, Balbi GGM, Aikawa NE, Silva CAA da, Kupa L de VK, Medeiros-Ribeiro AC, Yuki EFN, Pasoto SG, Saad CGS, Borba Neto EF, Bonfa ESD de O. Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome [Internet]. Lupus. 2022 ; 31( 8): 974-984.[citado 2024 nov. 10 ] Available from: https://doi.org/10.1177/09612033221102073
Vancouver
Signorelli F, Balbi GGM, Aikawa NE, Silva CAA da, Kupa L de VK, Medeiros-Ribeiro AC, Yuki EFN, Pasoto SG, Saad CGS, Borba Neto EF, Bonfa ESD de O. Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome [Internet]. Lupus. 2022 ; 31( 8): 974-984.[citado 2024 nov. 10 ] Available from: https://doi.org/10.1177/09612033221102073
Artigo de periodico
Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial (2022)
Araujo, Carlo Scognamiglio Renner; Medeiros-Ribeiro, Ana Cristina; Saad, Carla G. S; Bonfiglioli, Karina Rossi; Domiciano, Diogo Souza; Shimabuco, Andrea Yukie; Kupa, Leonard de Vinci Kanda ; Pereira, Rosa Maria Rodrigues ; Silva, Clovis Artur Almeida da ; Bonfa, Eloisa Silva Dutra de Oliveira
Source: Annals of the rheumatic diseases. Unidade: FM
Subjects: METOTREXATO, VACINAS VIRAIS, ARTRITE REUMATOIDE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ARAUJO, Carlo Scognamiglio Renner et al. Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial. Annals of the rheumatic diseases, v. 81, n. 6, p. 889-897, 2022Tradução . . Disponível em: https://doi.org/10.1136/annrheumdis-2021-221916. Acesso em: 10 nov. 2024.
APA
Araujo, C. S. R., Medeiros-Ribeiro, A. C., Saad, C. G. S., Bonfiglioli, K. R., Domiciano, D. S., Shimabuco, A. Y., et al. (2022). Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial. Annals of the rheumatic diseases, 81( 6), 889-897. doi:10.1136/annrheumdis-2021-221916
NLM
Araujo CSR, Medeiros-Ribeiro AC, Saad CGS, Bonfiglioli KR, Domiciano DS, Shimabuco AY, Kupa L de VK, Pereira RMR, Silva CAA da, Bonfa ESD de O. Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial [Internet]. Annals of the rheumatic diseases. 2022 ; 81( 6): 889-897.[citado 2024 nov. 10 ] Available from: https://doi.org/10.1136/annrheumdis-2021-221916
Vancouver
Araujo CSR, Medeiros-Ribeiro AC, Saad CGS, Bonfiglioli KR, Domiciano DS, Shimabuco AY, Kupa L de VK, Pereira RMR, Silva CAA da, Bonfa ESD de O. Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial [Internet]. Annals of the rheumatic diseases. 2022 ; 81( 6): 889-897.[citado 2024 nov. 10 ] Available from: https://doi.org/10.1136/annrheumdis-2021-221916
Artigo de periodico
Impact of distinct therapies on antibody response to SARS-CoV-2 vaccine in systemic lupus erythematosus (2022)
Yuki, Emily F. N; Borba Neto, Eduardo Ferreira ; Pasoto, Sandra G; Seguro, Luciana P; Lopes, Michelle; Saad, Carla G. S; Silva, Clovis Artur Almeida da ; Kupa, Leonard de Vinci Kanda ; Kallas, Esper Georges ; Bonfa, Eloisa Silva Dutra de Oliveira
Source: Arthritis care & research. Unidade: FM
Subjects: ANTICORPOS, VACINAS VIRAIS, COVID-19
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
YUKI, Emily F. N et al. Impact of distinct therapies on antibody response to SARS-CoV-2 vaccine in systemic lupus erythematosus. Arthritis care & research, v. 74, n. 4, p. 562-571, 2022Tradução . . Disponível em: https://doi.org/10.1002/acr.24824. Acesso em: 10 nov. 2024.
APA
Yuki, E. F. N., Borba Neto, E. F., Pasoto, S. G., Seguro, L. P., Lopes, M., Saad, C. G. S., et al. (2022). Impact of distinct therapies on antibody response to SARS-CoV-2 vaccine in systemic lupus erythematosus. Arthritis care & research, 74( 4), 562-571. doi:10.1002/acr.24824
NLM
Yuki EFN, Borba Neto EF, Pasoto SG, Seguro LP, Lopes M, Saad CGS, Silva CAA da, Kupa L de VK, Kallas EG, Bonfa ESD de O. Impact of distinct therapies on antibody response to SARS-CoV-2 vaccine in systemic lupus erythematosus [Internet]. Arthritis care & research. 2022 ; 74( 4): 562-571.[citado 2024 nov. 10 ] Available from: https://doi.org/10.1002/acr.24824
Vancouver
Yuki EFN, Borba Neto EF, Pasoto SG, Seguro LP, Lopes M, Saad CGS, Silva CAA da, Kupa L de VK, Kallas EG, Bonfa ESD de O. Impact of distinct therapies on antibody response to SARS-CoV-2 vaccine in systemic lupus erythematosus [Internet]. Arthritis care & research. 2022 ; 74( 4): 562-571.[citado 2024 nov. 10 ] Available from: https://doi.org/10.1002/acr.24824
Artigo de periodico
Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases (2022)
Aikawa, Nadia Emi; Kupa, Leonard de Vinci Kanda; Medeiros-Ribeiro, Ana Cristina; Saad, Carla Goncalves Schahin; Pereira, Rosa Maria Rodrigues ; Shinjo, Samuel Katsuyuki ; Sartori, Ana Marli Christovam ; Antonangelo, Leila ; Silva, Clovis Artur Almeida da ; Bonfa, Eloisa Silva Dutra de Oliveira
Source: Annals of the rheumatic diseases. Unidade: FM
Subjects: VACINAÇÃO, DOENÇAS AUTOIMUNES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
AIKAWA, Nadia Emi et al. Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases. Annals of the rheumatic diseases, v. 81, n. 7, p. 1036-1043, 2022Tradução . . Disponível em: https://doi.org/10.1136/annrheumdis-2021-222096. Acesso em: 10 nov. 2024.
APA
Aikawa, N. E., Kupa, L. de V. K., Medeiros-Ribeiro, A. C., Saad, C. G. S., Pereira, R. M. R., Shinjo, S. K., et al. (2022). Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases. Annals of the rheumatic diseases, 81( 7), 1036-1043. doi:10.1136/annrheumdis-2021-222096
NLM
Aikawa NE, Kupa L de VK, Medeiros-Ribeiro AC, Saad CGS, Pereira RMR, Shinjo SK, Sartori AMC, Antonangelo L, Silva CAA da, Bonfa ESD de O. Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases [Internet]. Annals of the rheumatic diseases. 2022 ; 81( 7): 1036-1043.[citado 2024 nov. 10 ] Available from: https://doi.org/10.1136/annrheumdis-2021-222096
Vancouver
Aikawa NE, Kupa L de VK, Medeiros-Ribeiro AC, Saad CGS, Pereira RMR, Shinjo SK, Sartori AMC, Antonangelo L, Silva CAA da, Bonfa ESD de O. Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases [Internet]. Annals of the rheumatic diseases. 2022 ; 81( 7): 1036-1043.[citado 2024 nov. 10 ] Available from: https://doi.org/10.1136/annrheumdis-2021-222096
Artigo de periodico
Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2 (2022)
Shinjo, Samuel Katsuyuki ; Souza, Fernando H. C. de; Borges, Isabela B. P; Santos, Alexandre M. Dos; Miossi, Renata; Misse, Rafael G; Medeiros-Ribeiro, Ana C; Kupa, Leonard de Vinci Kanda ; Silva, Clovis Artur Almeida da ; Bonfa, Eloisa Silva Dutra de Oliveira
Source: Rheumatology. Unidade: FM
Subjects: DOENÇAS AUTOIMUNES, VACINAS VIRAIS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SHINJO, Samuel Katsuyuki et al. Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2. Rheumatology, v. 61, n. 8, p. 3351-3361, 2022Tradução . . Disponível em: https://doi.org/10.1093/rheumatology/keab773. Acesso em: 10 nov. 2024.
APA
Shinjo, S. K., Souza, F. H. C. de, Borges, I. B. P., Santos, A. M. D., Miossi, R., Misse, R. G., et al. (2022). Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2. Rheumatology, 61( 8), 3351-3361. doi:10.1093/rheumatology/keab773
NLM
Shinjo SK, Souza FHC de, Borges IBP, Santos AMD, Miossi R, Misse RG, Medeiros-Ribeiro AC, Kupa L de VK, Silva CAA da, Bonfa ESD de O. Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2 [Internet]. Rheumatology. 2022 ; 61( 8): 3351-3361.[citado 2024 nov. 10 ] Available from: https://doi.org/10.1093/rheumatology/keab773
Vancouver
Shinjo SK, Souza FHC de, Borges IBP, Santos AMD, Miossi R, Misse RG, Medeiros-Ribeiro AC, Kupa L de VK, Silva CAA da, Bonfa ESD de O. Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2 [Internet]. Rheumatology. 2022 ; 61( 8): 3351-3361.[citado 2024 nov. 10 ] Available from: https://doi.org/10.1093/rheumatology/keab773
Artigo de periodico
Inactivated SARS-CoV-2 vaccine in primary Sjogren's syndrome: humoral response, safety, and effects on disease activity (2022)
Pasoto, Sandra Gofinet; Halpern, Ari Stiel Radu; Guedes, Lissiane Karine Noronha; Ribeiro, Ana Cristina Medeiros; Yuki, Emily Neves Figueiredo; Silva, Clovis Artur Almeida da ; Kupa, Leonard de Vinci Kanda ; Leon, Elaine Pires ; Bispo, Fabiana Renata Soares; Bonfa, Eloisa Silva Dutra de Oliveira
Source: Clinical rheumatology. Unidade: FM
Subjects: VACINAS VIRAIS, COVID-19, DOENÇAS AUTOIMUNES, ESTUDOS PROSPECTIVOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PASOTO, Sandra Gofinet et al. Inactivated SARS-CoV-2 vaccine in primary Sjogren's syndrome: humoral response, safety, and effects on disease activity. Clinical rheumatology, v. 41, n. 7, p. 2079-2089, 2022Tradução . . Disponível em: https://doi.org/10.1007/s10067-022-06134-x. Acesso em: 10 nov. 2024.
APA
Pasoto, S. G., Halpern, A. S. R., Guedes, L. K. N., Ribeiro, A. C. M., Yuki, E. N. F., Silva, C. A. A. da, et al. (2022). Inactivated SARS-CoV-2 vaccine in primary Sjogren's syndrome: humoral response, safety, and effects on disease activity. Clinical rheumatology, 41( 7), 2079-2089. doi:10.1007/s10067-022-06134-x
NLM
Pasoto SG, Halpern ASR, Guedes LKN, Ribeiro ACM, Yuki ENF, Silva CAA da, Kupa L de VK, Leon EP, Bispo FRS, Bonfa ESD de O. Inactivated SARS-CoV-2 vaccine in primary Sjogren's syndrome: humoral response, safety, and effects on disease activity [Internet]. Clinical rheumatology. 2022 ; 41( 7): 2079-2089.[citado 2024 nov. 10 ] Available from: https://doi.org/10.1007/s10067-022-06134-x
Vancouver
Pasoto SG, Halpern ASR, Guedes LKN, Ribeiro ACM, Yuki ENF, Silva CAA da, Kupa L de VK, Leon EP, Bispo FRS, Bonfa ESD de O. Inactivated SARS-CoV-2 vaccine in primary Sjogren's syndrome: humoral response, safety, and effects on disease activity [Internet]. Clinical rheumatology. 2022 ; 41( 7): 2079-2089.[citado 2024 nov. 10 ] Available from: https://doi.org/10.1007/s10067-022-06134-x
Artigo de periodico
Thalidomide measurement in plasma and dried plasma spot by SPE combined with UHPLC-MS/MS for therapeutic drug monitoring (2022)
Novellino, Renata Soares; Chalom, Marc Yves; Romano, Paschoalina; Ebner, Persio de Almeida Rezende; Seraphim, Julia Celestino; Amaral, Ana Carolina Silva do; Duarte, Nilo Jose Coelho; Silva, Clovis Artur Almeida da ; Bonfa, Eloisa Silva Dutra de Oliveira ; Kupa, Leonard de Vinci Kanda
Source: Bioanalysis. Unidade: FM
Subjects: LÚPUS ERITEMATOSO CUTÂNEO, FÁRMACOS DO SANGUE E SISTEMA HEMATOPOÉTICO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
NOVELLINO, Renata Soares et al. Thalidomide measurement in plasma and dried plasma spot by SPE combined with UHPLC-MS/MS for therapeutic drug monitoring. Bioanalysis, v. 14, n. 15, p. 1039-1050, 2022Tradução . . Disponível em: https://doi.org/10.4155/bio-2022-0077. Acesso em: 10 nov. 2024.
APA
Novellino, R. S., Chalom, M. Y., Romano, P., Ebner, P. de A. R., Seraphim, J. C., Amaral, A. C. S. do, et al. (2022). Thalidomide measurement in plasma and dried plasma spot by SPE combined with UHPLC-MS/MS for therapeutic drug monitoring. Bioanalysis, 14( 15), 1039-1050. doi:10.4155/bio-2022-0077
NLM
Novellino RS, Chalom MY, Romano P, Ebner P de AR, Seraphim JC, Amaral ACS do, Duarte NJC, Silva CAA da, Bonfa ESD de O, Kupa L de VK. Thalidomide measurement in plasma and dried plasma spot by SPE combined with UHPLC-MS/MS for therapeutic drug monitoring [Internet]. Bioanalysis. 2022 ; 14( 15): 1039-1050.[citado 2024 nov. 10 ] Available from: https://doi.org/10.4155/bio-2022-0077
Vancouver
Novellino RS, Chalom MY, Romano P, Ebner P de AR, Seraphim JC, Amaral ACS do, Duarte NJC, Silva CAA da, Bonfa ESD de O, Kupa L de VK. Thalidomide measurement in plasma and dried plasma spot by SPE combined with UHPLC-MS/MS for therapeutic drug monitoring [Internet]. Bioanalysis. 2022 ; 14( 15): 1039-1050.[citado 2024 nov. 10 ] Available from: https://doi.org/10.4155/bio-2022-0077
Artigo de periodico
SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy (2022)
Sampaio-Barros, Percival Degrava; Medeiros-Ribeiro, Ana Cristina; Luppino-Assad, Ana Paula; Miossi, Renata; Silva, Henrique Carrico da; Yuki, Emily F. V. N; Pasoto, Sandra G; Saad, Carla G. S; Silva, Clovis Artur Almeida da ; Kupa, Leonard de Vinci Kanda ; Bonfa, Eloisa Silva Dutra de Oliveira
Source: Rheumatology. Unidade: FM
Subjects: PEDIATRIA, DOENÇAS NEONATAIS E ANORMALIDADES, ANTIBIÓTICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SAMPAIO-BARROS, Percival Degrava et al. SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy. Rheumatology, v. 61, n. SI2, p. SI169-SI174, 2022Tradução . . Disponível em: https://doi.org/10.1093/rheumatology/keab886. Acesso em: 10 nov. 2024.
APA
Sampaio-Barros, P. D., Medeiros-Ribeiro, A. C., Luppino-Assad, A. P., Miossi, R., Silva, H. C. da, Yuki, E. F. V. N., et al. (2022). SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy. Rheumatology, 61( SI2), SI169-SI174. doi:10.1093/rheumatology/keab886
NLM
Sampaio-Barros PD, Medeiros-Ribeiro AC, Luppino-Assad AP, Miossi R, Silva HC da, Yuki EFVN, Pasoto SG, Saad CGS, Silva CAA da, Kupa L de VK, Bonfa ESD de O. SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy [Internet]. Rheumatology. 2022 ; 61( SI2): SI169-SI174.[citado 2024 nov. 10 ] Available from: https://doi.org/10.1093/rheumatology/keab886
Vancouver
Sampaio-Barros PD, Medeiros-Ribeiro AC, Luppino-Assad AP, Miossi R, Silva HC da, Yuki EFVN, Pasoto SG, Saad CGS, Silva CAA da, Kupa L de VK, Bonfa ESD de O. SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy [Internet]. Rheumatology. 2022 ; 61( SI2): SI169-SI174.[citado 2024 nov. 10 ] Available from: https://doi.org/10.1093/rheumatology/keab886
Artigo de periodico
Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study (2022)
Aikawa, Nadia E; Kupa, Leonard de Vinci Kanda ; Pasoto, Sandra Gofinet; Shinjo, Samuel Katsuyuki ; Pereira, Rosa Maria Rodrigues ; Sartori, Ana Marli Christovam ; Duarte, Alberto José da Silva; Antonangelo, Leila ; Sabino, Ester Cerdeira ; Menezes, Paulo Rossi ; Kallas, Esper Georges ; Silva, Clovis Artur Almeida da ; Bonfa, Eloisa Silva Dutra de Oliveira
Source: Lancet rheumatology. Unidade: FM
Subjects: IMUNOGENÉTICA, COVID-19, SISTEMA IMUNE, IMUNOGENICIDADE DA VACINA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
AIKAWA, Nadia E et al. Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study. Lancet rheumatology, v. 4, n. 2, p. E113-E124, 2022Tradução . . Disponível em: https://doi.org/10.1016/S2665-9913(21)00327-1. Acesso em: 10 nov. 2024.
APA
Aikawa, N. E., Kupa, L. de V. K., Pasoto, S. G., Shinjo, S. K., Pereira, R. M. R., Sartori, A. M. C., et al. (2022). Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study. Lancet rheumatology, 4( 2), E113-E124. doi:10.1016/S2665-9913(21)00327-1
NLM
Aikawa NE, Kupa L de VK, Pasoto SG, Shinjo SK, Pereira RMR, Sartori AMC, Duarte AJ da S, Antonangelo L, Sabino EC, Menezes PR, Kallas EG, Silva CAA da, Bonfa ESD de O. Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study [Internet]. Lancet rheumatology. 2022 ; 4( 2): E113-E124.[citado 2024 nov. 10 ] Available from: https://doi.org/10.1016/S2665-9913(21)00327-1
Vancouver
Aikawa NE, Kupa L de VK, Pasoto SG, Shinjo SK, Pereira RMR, Sartori AMC, Duarte AJ da S, Antonangelo L, Sabino EC, Menezes PR, Kallas EG, Silva CAA da, Bonfa ESD de O. Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study [Internet]. Lancet rheumatology. 2022 ; 4( 2): E113-E124.[citado 2024 nov. 10 ] Available from: https://doi.org/10.1016/S2665-9913(21)00327-1
Artigo de periodico-dep/entr
Professores da Poli recebem a medalha “Armando de Salles Oliveira” da USP (2021)
González Lima, Raúl ; Zuffo, Marcelo Knörich ; Bonfa, Eloisa Silva Dutra de Oliveira ; Sabino, Ester Cerdeira ; Kallás, Esper Georges ; Saldiva, Paulo Hilário Nascimento
Source: PoliInforma Semanal -Informativo da Escola Politécnica da USP. Trajetórias Politécnicas. Unidades: EP, FM
Subjects: MEDALHAS, CONCESSÃO DE SERVIÇO PÚBLICO, UNIVERSIDADE PÚBLICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GONZÁLEZ LIMA, Raúl et al. Professores da Poli recebem a medalha “Armando de Salles Oliveira” da USP. PoliInforma Semanal -Informativo da Escola Politécnica da USP. Trajetórias Politécnicas. Sao Paulo: Escola Politécnica, Universidade de São Paulo. Disponível em: https://www.youtube.com/watch?v=Ybvi3dk9ObU. Acesso em: 10 nov. 2024. , 2021
APA
González Lima, R., Zuffo, M. K., Bonfa, E. S. D. de O., Sabino, E. C., Kallás, E. G., & Saldiva, P. H. N. (2021). Professores da Poli recebem a medalha “Armando de Salles Oliveira” da USP. PoliInforma Semanal -Informativo da Escola Politécnica da USP. Trajetórias Politécnicas. Sao Paulo: Escola Politécnica, Universidade de São Paulo. Recuperado de https://www.youtube.com/watch?v=Ybvi3dk9ObU
NLM
González Lima R, Zuffo MK, Bonfa ESD de O, Sabino EC, Kallás EG, Saldiva PHN. Professores da Poli recebem a medalha “Armando de Salles Oliveira” da USP [Internet]. PoliInforma Semanal -Informativo da Escola Politécnica da USP. Trajetórias Politécnicas. 2021 ;[citado 2024 nov. 10 ] Available from: https://www.youtube.com/watch?v=Ybvi3dk9ObU
Vancouver
González Lima R, Zuffo MK, Bonfa ESD de O, Sabino EC, Kallás EG, Saldiva PHN. Professores da Poli recebem a medalha “Armando de Salles Oliveira” da USP [Internet]. PoliInforma Semanal -Informativo da Escola Politécnica da USP. Trajetórias Politécnicas. 2021 ;[citado 2024 nov. 10 ] Available from: https://www.youtube.com/watch?v=Ybvi3dk9ObU

USP Schools

ReP

Filtros

Departament

Authors

USP affiliated authors

Subjects

Source title

Funding Agencies